{"title":"长效β受体激动剂及其与哮喘发病率和死亡率增加的关系。FDA荟萃分析","authors":"G. Pesola, T. Lone, Ramani Gosala","doi":"10.5580/60b","DOIUrl":null,"url":null,"abstract":"When long-acting beta-agonists (LABA) were initially introduced overseas, salmeterol was compared head to head with albuterol in a randomized, double blind study over 16 weeks (1) in addition to usual asthma care. There was a 3fold greater probability of death with the use of salmeterol (12/16,787) compared to albuterol (2/8,393). This outcome comparison did not reach statistical significance and the results did not address the issue of the use of inhaled steroids as background treatment with LABA. In the U.S. the FDA requested GlaxoSmithKline obtain more data related to its product salmeterol, sold as Serevent or Advair and this resulted in the SMART study.","PeriodicalId":161194,"journal":{"name":"The Internet Journal of Dermatology","volume":"7 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Long-Acting Beta agonists and their relation to increased Asthma Morbidity and Mortality. The FDA Meta-Analysis\",\"authors\":\"G. Pesola, T. Lone, Ramani Gosala\",\"doi\":\"10.5580/60b\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"When long-acting beta-agonists (LABA) were initially introduced overseas, salmeterol was compared head to head with albuterol in a randomized, double blind study over 16 weeks (1) in addition to usual asthma care. There was a 3fold greater probability of death with the use of salmeterol (12/16,787) compared to albuterol (2/8,393). This outcome comparison did not reach statistical significance and the results did not address the issue of the use of inhaled steroids as background treatment with LABA. In the U.S. the FDA requested GlaxoSmithKline obtain more data related to its product salmeterol, sold as Serevent or Advair and this resulted in the SMART study.\",\"PeriodicalId\":161194,\"journal\":{\"name\":\"The Internet Journal of Dermatology\",\"volume\":\"7 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Internet Journal of Dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5580/60b\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Internet Journal of Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5580/60b","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Long-Acting Beta agonists and their relation to increased Asthma Morbidity and Mortality. The FDA Meta-Analysis
When long-acting beta-agonists (LABA) were initially introduced overseas, salmeterol was compared head to head with albuterol in a randomized, double blind study over 16 weeks (1) in addition to usual asthma care. There was a 3fold greater probability of death with the use of salmeterol (12/16,787) compared to albuterol (2/8,393). This outcome comparison did not reach statistical significance and the results did not address the issue of the use of inhaled steroids as background treatment with LABA. In the U.S. the FDA requested GlaxoSmithKline obtain more data related to its product salmeterol, sold as Serevent or Advair and this resulted in the SMART study.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
